Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

1.4K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.4K
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

1.4K
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
1.4K
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

830
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
830
Analgesia and Pain Management01:25

Analgesia and Pain Management

2.8K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.8K
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

6.1K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
6.1K
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

138
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
138

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Food and Drug Administration recommends against the continued use of propoxyphene.

Journal of pain & palliative care pharmacotherapy·2011
See all related articles

Related Experiment Video

Updated: Mar 19, 2026

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs
10:13

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs

Published on: November 8, 2024

3.0K

FDA Boxed Warning for Immediate-Release Opioids.

Food And Drug Administration Public Health Service U S Department Of Health And Human Services

    Journal of Pain & Palliative Care Pharmacotherapy
    |June 16, 2016
    PubMed
    Summary

    The Food and Drug Administration (FDA) issued stronger warnings for opioid pain relievers due to serious risks. These enhanced safety communications alert prescribers and patients to dangers like addiction and overdose.

    Area of Science:

    • Pharmacology
    • Public Health
    • Regulatory Science

    Background:

    • Opioid pain medications are widely prescribed for various pain conditions.
    • Concerns regarding misuse, abuse, addiction, overdose, and death associated with opioid use have been rising.
    • Existing safety information for opioid medications needed augmentation to reflect current understanding of risks.

    Purpose of the Study:

    • To announce and detail the enhanced safety warnings issued by the Food and Drug Administration (FDA) for opioid pain medications.
    • To inform healthcare providers and patients about the updated risk information.
    • To emphasize the potential dangers associated with both immediate-release and all prescription opioid medications.

    Main Methods:

    • Review and analysis of post-marketing safety data for opioid medications.
    Keywords:
    boxedimmediate releaseopioidswarning

    More Related Videos

    Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
    09:54

    Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

    Published on: March 8, 2020

    5.7K
    Author Spotlight: A Novel 3D-Printed Titanium Implant for Minimally Invasive Treatment of Hip Dysplasia in Young Dogs
    08:40

    Author Spotlight: A Novel 3D-Printed Titanium Implant for Minimally Invasive Treatment of Hip Dysplasia in Young Dogs

    Published on: April 19, 2024

    4.0K

    Related Experiment Videos

    Last Updated: Mar 19, 2026

    Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs
    10:13

    Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs

    Published on: November 8, 2024

    3.0K
    Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
    09:54

    Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

    Published on: March 8, 2020

    5.7K
    Author Spotlight: A Novel 3D-Printed Titanium Implant for Minimally Invasive Treatment of Hip Dysplasia in Young Dogs
    08:40

    Author Spotlight: A Novel 3D-Printed Titanium Implant for Minimally Invasive Treatment of Hip Dysplasia in Young Dogs

    Published on: April 19, 2024

    4.0K
  • Evaluation of the risk-benefit profile of immediate-release opioid pain relievers.
  • Issuance of updated safety labeling and communication to the public.

    • Main Results:

    • The FDA announced enhanced warnings for immediate-release opioid pain medications on March 22, 2016.
    • These warnings specifically address risks of misuse, abuse, addiction, overdose, and death.
    • Additional safety information regarding broader risks was incorporated into labeling for all prescription opioid medications.

    Conclusions:

    • Enhanced regulatory oversight is crucial for managing the risks of prescription opioid medications.
    • Clear and comprehensive communication of risks to prescribers and patients is essential for safe opioid use.
    • The FDA's actions underscore the ongoing commitment to patient safety in opioid therapy.